Possible influence of the mutant CCR5 allele on vertical transmission of HIV-1

被引:0
|
作者
Mandl, CW [1 ]
Aberle, SW [1 ]
Henkel, JH [1 ]
Puchhammer-Stöckl, E [1 ]
Heinz, FX [1 ]
机构
[1] Univ Vienna, Inst Virol, A-1095 Vienna, Austria
关键词
co-receptor CCR5; vertical transmission; resistance to HIV-1;
D O I
10.1002/(SICI)1096-9071(199805)55:1<51::AID-JMV9>3.3.CO;2-Q
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A possible correlation between the rate of vertical transmission of HIV-1 and the presence of the defective HIV co-receptor gene Delta 32ccr5 in the chromosomes of infants born to HIV-positive mothers was assessed. The prevalence and genotypic distribution of the Delta 32ccr5 gene were studied in 451 uninfected and 225 HIV-l-infected adults and 79 children born to HIV-1-positive mothers in Austria (45 uninfected and 34 infected by vertical transmission). As expected in a Caucasian population, the Delta 32ccr5 allele was found in uninfected Austrians at a frequency of 10% (17.3% heterozygotes and 1.3% Delta 32ccr5/Delta 32ccr5 homozygotes, consistent with the expected Hardy-Weinberg distribution). The mutant allele frequency was 11.1% in uninfected children (17.8% heterozygotes, 2.2% homozygotes) and 9.6% in HIV-positive adults (19.1% heterozygotes but no Delta 32ccr5/Delta 32ccr5 homozygotes). Among the group of 34 vertically infected children, however, there were only two heterozygotes and no Delta 32ccr5/Delta 32ccr5 homozygotes, corresponding to a significantly reduced mutant allele frequency of 2.9% (P = 0.05 compared to HIV-negative children). These results suggest that CCR5/Delta 32ccr5 heterozygous children are less susceptible to vertical transmission of HIV-1. The data also support the hypothesis that Delta 32ccr5 homozygous individuals are resistant to HIV-1 infection. (C) 1998 Wiley-Liss, Inc.
引用
收藏
页码:51 / 55
页数:5
相关论文
共 50 条
  • [41] CCR5 Utilization of Transmitted and Early Founder HIV-1 Envelopes and the Sensitivity to Small CCR5 Inhibitors
    Hu, Q.
    Keele, B.
    Ping, L.
    Grayson, T.
    Sun, C.
    Hahn, B.
    Shattock, R.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 6 - 6
  • [42] CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1
    Bredeek, U. Fritz
    Harbour, Michael J.
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 427 - 434
  • [43] Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors
    Henrich, T. J.
    Lewine, N.
    Lee, S-H
    Rao, S.
    Berro, R.
    Greaves, W.
    Gulick, R.
    Tsibris, A.
    Moore, J.
    Kuritzkes, D.
    [J]. ANTIVIRAL THERAPY, 2011, 16 : A59 - A59
  • [44] CCR5, RANTES and SDF-1 polymorphisms and mother-to-child HIV-1 transmission
    Katz, D. A.
    John-Stewart, G. C.
    Richardson, B. A.
    Majiwa, M.
    Mabuka, J. M.
    Lohman-Payne, B.
    Farquhar, C.
    [J]. INTERNATIONAL JOURNAL OF IMMUNOGENETICS, 2010, 37 (04) : 301 - 305
  • [45] Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands
    Ketas, Thomas J.
    Kuhmann, Shawn E.
    Palmer, Ashley
    Zurita, Juan
    He, Weijing
    Ahuja, Sunil K.
    Klasse, Per Johan
    Moore, John P.
    [J]. VIROLOGY, 2007, 364 (02) : 281 - 290
  • [46] Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression
    Smith, MW
    Dean, M
    Carrington, M
    Winkler, C
    Huttley, GA
    Lomb, DA
    Goedert, JJ
    OBrien, TR
    Jacobson, LP
    Kaslow, R
    Buchbinder, S
    Vittinghoff, E
    Vlahov, D
    Hoots, K
    Hilgartner, MW
    OBrien, SJ
    [J]. SCIENCE, 1997, 277 (5328) : 959 - 965
  • [47] Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry
    Nahabedian, John
    Sharma, Amit
    Kaczmarek, Maryska E.
    Wilkerson, Greg K.
    Sawyer, Sara L.
    Overbaugh, Julie
    [J]. VIROLOGY, 2017, 512 : 180 - 186
  • [48] CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists
    Miller, MD
    Lineberger, JE
    Dornadula, G
    Danzeisen, RC
    Blau, CR
    Danovich, RM
    Miller, MA
    Finke, PE
    Oates, BD
    Caldwell, CG
    Chen, P
    Meurer, LC
    Mills, SG
    Springer, MS
    Petropoulos, CJ
    Whitcomb, J
    Huang, W
    Fransen, S
    Simon, AJ
    Hazuda, DJ
    [J]. ANTIVIRAL THERAPY, 2003, 8 (03) : U66 - U67
  • [49] Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Soulie, Cathia
    Malet, Isabelle
    Lambert-Niclot, Sidonie
    Tubiana, Roland
    Thevenin, Monique
    Simon, Anne
    Murphy, Robert
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    [J]. AIDS, 2008, 22 (16) : 2212 - 2214
  • [50] Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
    Henrich, Timothy J.
    Lewine, Nicolas R. P.
    Lee, Sun-Hee
    Rao, Suhas S. P.
    Berro, Reem
    Gulick, Roy M.
    Moore, John P.
    Tsibris, Athe M. N.
    Kuritzkes, Daniel R.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) : 1931 - 1935